Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sunahara, S.
Right arrow Articles by Nakagawa, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sunahara, S.
Right arrow Articles by Nakagawa, H.
(Chest. 1972;61:526-532.)
© 1972 American College of Chest Physicians

Metabolic Study and Controlled Clinical Trials of Rifampin

Shigeichi Sunahara M.D.1 and Hideo Nakagawa M.D.1

1 Tokyo National Chest Hospital, 3-1-1, Takeoka, Kiyose City, Tokyo, Japan

A new biochemical technique for the determination of rifampin and desacetylrifampicin in body fluid was developed. Identification of rifampin metabolites in human urine was carried out. Rifampin oxidizing activity of human saliva was noticed and the nature of the active substance was investigated.

Controlled clinical trials on initial treatment and retreatment were conducted and it was revealed that rifampin was a very important antituberculostatic agent.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1972 by the American College of Chest Physicians.